BioCentury
ARTICLE | Company News

Nventa infectious, genitourinary, cancer news

October 13, 2008 7:00 AM UTC

Nventa will restructure and reduce headcount by 60% to 5 to reduce cash burn by 30%. The company will seek alternatives, including M&A or partners for lead compound HspE7 and its preclinical compound...